Blogging Journal San Diego Venture Capital 
Xconomy
JULY 26, 2016
Adding to the confusion, the most-recent MoneyTree Report on San Diego venture capital activity shows that Ostendo raised almost $10 million in VC funding during the second quarter. It’s unclear, though, if the $41.8 million disclosed in a July 14 filing includes $27.3M
Xconomy
JULY 17, 2020
In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. The figures come from the National Venture Capital Association and financial research firm Pitchbook.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
AUGUST 16, 2016
A recent Wall Street Journal article that raised the possibility of Biogen as the target of another huge pharma buyout cited the lack of productivity as a major driver of M&A in the pharmaceutical industry. Yet despite relative plenty in the bio-venture community, pharma suffers from a shortage of drug candidates.
Xconomy
NOVEMBER 14, 2017
Other investors in the firm include Mayfield , Menlo Ventures , GGV Capital , Inventus Capital , SoftTech VC , Union Grove Venture Partners , and Cross Creek Advisors. That brings the total funding raised by the Redwood City, CA-based company to $160 million.
Xconomy
SEPTEMBER 19, 2016
Charley Grant, writing in The Wall Street Journal , commented that, “Any action to curb price increases on older drugs would hurt manufacturers that rely on them to generate growth.” In his blog Bruce Booth of Atlas Ventures contrasted “exploiters and innovators,” the former a subset of the generic industry. It has started.”
Xconomy
SEPTEMBER 6, 2019
Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have to steal away. But the first mover isn’t infallible if someone else has something better. is counting on.
Xconomy
APRIL 20, 2018
The biggest news this week was in oncology, hands down. Merck showed that its immunotherapy pembrolizumab (Keytruda) might become a common option for many patients newly diagnosed with advanced lung cancer, but the bigger picture is that the field is moving fast.
Expert insights. Personalized for you.
40 
Let's personalize your content